PR Newswire
AUSTIN, Texas
,
March 29, 2022
/PRNewswire/ — Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced poster presentations at two upcoming medical meetings. The Company will present additional data from the PEACE Phase 3 study of pegzilarginase for the treatment of patients with Arginase 1 Deficiency (ARG1-D) at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting in
Orlando, FL.
Additionally, two encore posters describing the management of ARG1-D and the role of arginine as a key driver of the disease will be presented at the American Academy of Neurology (AAN) Annual Meeting in
Seattle, WA
and virtually.
Society for Inherited Metabolic Disorders Annual Meeting (
April 10-13, 2022
)
Title: Pegzilarginase in Arginase 1 Deficiency: Results of the PEACE Pivotal Phase 3 Clinical Trial
Abstract: #30
Session: Scientific Session 5
Presentation time:
Monday, April 11
from
7-8pm PDT
Presenter:
Eric Bradford
, MD, MSc, MBA, chief development officer at Aeglea BioTherapeutics
American Academy of Neurology Annual Meeting (Live:
April 2-7, 2022
; Virtual:
April 24-26, 2022
)
Title: Management and Progression of Arginase 1 Deficiency Over 2 Decades of Follow-Up
Abstract: 003
Session: P11
Presentation time:
Tuesday, April 5
from
11:45am-12:45pm EDT
Presenter:
Deborah Marsden
, MBBS, FAMCGG, MRCP(UK), attending physician, Division of Genetics and Genomics at Boston Children’s Hospital
Title: Arginine: The Key Driver of Pathophysiology and Progression in Arginase 1 Deficiency
Abstract: 004
Session: P11
Presentation time:
Tuesday, April 5
from
11:45am-12:45pm EDT
Presenter:
Mark Bechter
, BM, vice president of medical affairs at Aeglea BioTherapeutics
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. In
December 2021
, Aeglea announced positive topline data from its PEACE Phase 3 clinical trial for its lead product candidate, pegzilarginase, in patients with Arginase 1 Deficiency. Pegzilarginase has received both Rare Pediatric Disease and Breakthrough Therapy Designations. Aeglea also has an ongoing Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families. For more information, please visit
.
View original content to download multimedia:
https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-announces-presentation-of-additional-data-from-peace-phase-3-study-of-pegzilarginase-for-the-treatment-of-arginase-1-deficiency-at-the-society-for-inherited-metabolic-disorders-annual-meeting-301511845.html
SOURCE Aeglea BioTherapeutics, Inc.
